Commercial

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Formycon has again stepped closer to financial certainty with another pembrolizumab biosimilar deal. This time, it unlocked a significant opportunity for the US and Canadian markets.

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

With Gilead reporting that both of its approved CAR-Ts saw sales declines as other products saw growth, a mixture of different competitive headwinds seems to be behind the disparities.

European Commission approval positions Celltrion to streamline hospital workflows, with modelling suggesting millions in potential annual savings for healthcare systems.

Deal gives NTC exclusive rights to commercialize Formycon and Klinge’s Baiama aflibercept biosimilar in Italy, expanding Formycon’s growing network of European ophthalmology partners.

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.